All
Rethinking recruitment & retention
May 1st 2004National report - Aware of a shortage of medical personnel in the Philadelphia region, physician assistant Abby Jacobson was confident she would easily land a new job when she found out her supervising physician was selling his practice. She not only got a new position within a few weeks at a dermatology practice, but she received a salary increase, and negotiated a four-day workweek with Fridays off.
Aastrom Biosciences Inc. receives Phase I Small Business Innovation Research Grant (SBIR)
April 22nd 2004Aastrom Biosciences Inc. announced that it has received a Phase I Small Business Innovation Research Grant (SBIR) grant from the National Institutes of Health National Cancer Institute to develop an immunotherapeutic treatment of malignant melanoma using its AastromReplicell System cell production technology.
United Research Laboratories and Mutual Pharmaceutical Co. launch generic version of Periostat
April 16th 2004Source: www.drugfacts.com United Research Laboratories / Mutual Pharmaceutical Co. announced the launch of a generic version of CollaGenex Pharmaceutical Inc.?s Periostat (doxycycline hyclate) tablets.
Ceplene/Interleukin-2 combination approved for treatment of malignant melanoma
April 14th 2004Source: www.pharmalive.com Maxim Pharmaceuticals announced that its treatment protocol to provide its investigational drug Ceplene, in combination with interleukin-2 (IL-2), for treatment of patients with advanced malignant melanoma, has been approved by the FDA. The protocol allows Maxim to provide expanded access of Ceplene to patients in the United States while a Phase III clinical trial continues.
FDA accepts Connetics Corp. NDA filing for Extina
April 8th 2004Source: www.PRNewswire.com Connetics Corp., a specialty pharmaceutical company focused on dermatology announced Thursday, April 8 that it has received confirmation that the FDA has accepted for filing the company's NDA for Extina, as of Jan. 26, 2004, with a user fee goal date of Sept. 24, 2004.
Dissecting cellulitis responds to Nd:YAG laser
April 1st 2004Washington D.C. - In a recent trial involving four patients with dissecting cellulitis, long-pulsed Nd:YAG (1,064 nm) laser treatments were shown to reduce pain, purulent drainage, and the need for systemic antibiotics. In addition, some patients' hair regrew without recurrence of the disease.
Filler frenzy is cause for consideration
April 1st 2004New York - As injectable filler options grow, so do their power to offer patients a second round of youthful looks. The market is expanding with fillers that offer various compositions, indications, durations of effect, and stages of FDA approval. The growing choices are cause for celebration and consideration.
Simple fat transfer approach avoids sharp needles
April 1st 2004New York - Imagine fat as a substance bundled into intact parcels that are a size and shape allowing for them to travel through a small cannula - both when harvested and injected. This is the key to transferring the permanent subcutaneous filler, Sydney R. Coleman, M.D. said.
Exercise should correct posture, lengthen spine, strengthen muscles
April 1st 2004San Diego - Much of the aging process is about gravity trying to pull us out through the soles of our feet, and eventually it succeeds, said Michael Colgan, Ph.D. A physiologist and biochemist, Colgan called humans "the most domesticated animal" and said that our sedentary habits exacerbate the impact of gravity.